NCT00638898 2025-03-20
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Phase 1 Completed
Clinical Trials
11 trialsNCT01505569 2024-02-26
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT00019968 2023-10-31
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00043979 2017-05-31
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00357396 2015-11-25
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00112645 2013-07-18
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003425 2013-04-26
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
University of Kentucky
Phase 1/2 Completed
NCT00004250 2013-01-16
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003081 2010-09-20
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00165139 2009-11-02
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00001577 2008-03-04
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
National Institutes of Health Clinical Center (CC)
Phase 1 Completed